Publications
Detailed Information
N-Hydroxy-7-(2-naphthylthio) Heptanomide Inhibits Retinal and Choroidal Angiogenesis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jeong Hun | - |
dc.contributor.author | Kim, Jin Hyoung | - |
dc.contributor.author | Oh, Meeyeon | - |
dc.contributor.author | Yu, Young Suk | - |
dc.contributor.author | Kwon, Ho Jeong | - |
dc.contributor.author | Kim, Kyu-Won | - |
dc.date.accessioned | 2012-07-02T00:58:53Z | - |
dc.date.available | 2012-07-02T00:58:53Z | - |
dc.date.issued | 2009-04 | - |
dc.identifier.citation | MOLECULAR PHARMACEUTICS; Vol.6 2; 513-519 | ko_KR |
dc.identifier.issn | 1543-8384 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78028 | - |
dc.description.abstract | Histone deacetylase (HDAC) is a key enzyme regulating gene expression, including angiogenic cytokine expression. We have previously identified a novel synthetic HDAC inhibitor, known as N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), with antitumor properties. Here, we investigated the antiangiogenic properties of this small synthetic molecule both in vitro and in vivo. HNHA inhibited nuclear HDAC enzyme activity in human umbilical endothelial cells (HUVECs), an effect accompanied by histone hyperacetylation, p21 upregulation, and cell cycle arrest. HNHA also inhibited vascular endothelial growth factor-induced tube formation and migration of HUVECs, in the absence of any detectable cellular toxicity. Intravitreous injection of HNHA into mice inhibited retinal neovascularization associated with oxygen-induced retinopathy (OIR) and laser-induced choroidal neovascularization (CNV), as determined through fluorescence angiography and vessel counting. Retinas from HNHA-treated animals had a normal histological appearance without any detectable increase in terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeliing-positive cells, showing that this compound did not induce retinal toxicity. These findings indicate that HNHA has direct antiangiogenic effects and may be an effective strategy for inhibiting the pathological retinal and choroidal neovascularization underlying blinding eye diseases. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | AMER CHEMICAL SOC | ko_KR |
dc.subject | Anti-angiogenesis | ko_KR |
dc.subject | retinal neovascularization | ko_KR |
dc.subject | N-hydroxy-7-(2-naphthylthio) heptanomide | ko_KR |
dc.subject | choroidal neovascularization | ko_KR |
dc.subject | histone deacetylase inhibitor | ko_KR |
dc.title | N-Hydroxy-7-(2-naphthylthio) Heptanomide Inhibits Retinal and Choroidal Angiogenesis | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김정훈 | - |
dc.contributor.AlternativeAuthor | 김진형 | - |
dc.contributor.AlternativeAuthor | 오미연 | - |
dc.contributor.AlternativeAuthor | 유영석 | - |
dc.contributor.AlternativeAuthor | 김규원 | - |
dc.contributor.AlternativeAuthor | 권호정 | - |
dc.identifier.doi | 10.1021/mp800178b | - |
dc.citation.journaltitle | MOLECULAR PHARMACEUTICS | - |
dc.description.citedreference | Kim JH, 2008, J PHARMACOL EXP THER, V324, P643, DOI 10.1124/jpet.107.132720 | - |
dc.description.citedreference | KIM JH, 2008, J CELL MOL MED | - |
dc.description.citedreference | Kim JH, 2007, BIOCHEM BIOPH RES CO, V362, P848, DOI 10.1016/j.bbrc.2007.08.100 | - |
dc.description.citedreference | Kim DH, 2007, BIOCHEM BIOPH RES CO, V356, P233, DOI 10.1016/j.bbrc.2007.02.126 | - |
dc.description.citedreference | Min JK, 2007, BLOOD, V109, P1495, DOI 10.1182/blood-2006-06-029298 | - |
dc.description.citedreference | Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247 | - |
dc.description.citedreference | CHEN J, 2007, ANGIOGENESIS, V10, P133, DOI 10.1007/s10456-007-9066-0 | - |
dc.description.citedreference | Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annutev.med.57.121304.131306 | - |
dc.description.citedreference | Parker M, 2006, J BIOSOC SCI, V38, P117, DOI 10.1017/S0021932005001136 | - |
dc.description.citedreference | Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111 | - |
dc.description.citedreference | Sasakawa Y, 2003, BIOCHEM PHARMACOL, V66, P897, DOI 10.1016/S0006-2952(03)00411-8 | - |
dc.description.citedreference | Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100 | - |
dc.description.citedreference | Zhang Y, 2003, EMBO J, V22, P1168 | - |
dc.description.citedreference | Matsuyama A, 2002, EMBO J, V21, P6820 | - |
dc.description.citedreference | Deroanne CF, 2002, ONCOGENE, V21, P427 | - |
dc.description.citedreference | Kim MS, 2001, NAT MED, V7, P437 | - |
dc.description.citedreference | Han JW, 2000, CANCER RES, V60, P6068 | - |
dc.description.citedreference | Xiao HY, 1999, J CELL BIOCHEM, V73, P291 | - |
dc.description.citedreference | Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791 | - |
dc.description.citedreference | Grunstein M, 1997, NATURE, V389, P349 | - |
dc.description.citedreference | Hassig CA, 1997, CELL, V89, P341 | - |
dc.description.citedreference | Risau W, 1997, NATURE, V386, P671 | - |
dc.description.citedreference | Pierce EA, 1996, ARCH OPHTHALMOL-CHIC, V114, P1219 | - |
dc.description.citedreference | Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705 | - |
dc.description.citedreference | Taunton J, 1996, SCIENCE, V272, P408 | - |
dc.description.citedreference | AIELLO LP, 1994, NEW ENGL J MED, V331, P1480 | - |
dc.description.citedreference | SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101 | - |
dc.description.citedreference | HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109 | - |
dc.description.citedreference | MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644 | - |
dc.description.citedreference | ROTH AM, 1977, AM J OPHTHALMOL, V84, P636 | - |
dc.description.tc | 2 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.